Taken together, the CRY stabilizer, TH301, demonstrates a superior efficacy in reducing human pancreatic cancer cell viability and growth, compared to other CRY modulators tested herein (KL001 and KS15). This evidence concerns the gene CRYL1 and familial pancreatic carcinoma.